Evidence map›Paper›PMID 27817059›Full record

ArticleCancer chemotherapy and pharmacology2016

Matthew Scarpelli, Justine Yang Bruce, Lakeesha Carmichael, Jens Eickhoff, Jill Kolesar, Scott Perlman, Robert Jeraj, Glenn Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Matthew ScarpelliDepartment of Medical Physics, Wisconsin Institute for Medical Research, University of Wisconsin, Room 1005, 1111 Highland Ave, Madison, WI, 53705, USA.
Justine Yang BruceDivision of Hematology/Oncology, Department of Medicine, Wisconsin Institute for Medical Research, University of Wisconsin, Room 7105, 1111 Highland Ave, Madison, WI, 53705, USA. jybruce@medicine.wisc.edu.
Lakeesha CarmichaelDepartment of Biostatistics and Medical Informatics, K6/422 Clinical Science Center, University of Wisconsin, MC 4675, 600 Highland Ave, Madison, WI, 53792, USA.
Jens EickhoffUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin, 600 Highland Ave, Madison, WI, 53792, USA.
Jill KolesarUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin, 600 Highland Ave, Madison, WI, 53792, USA.
Scott PerlmanUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin, 600 Highland Ave, Madison, WI, 53792, USA.
Robert JerajDepartment of Medical Physics, Wisconsin Institute for Medical Research, University of Wisconsin, Room 1005, 1111 Highland Ave, Madison, WI, 53705, USA.
Glenn LiuDepartment of Medical Physics, Wisconsin Institute for Medical Research, University of Wisconsin, Room 1005, 1111 Highland Ave, Madison, WI, 53705, USA.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
NCI NIH HHS P30 CA014520
6 · The paper itself

Abstract

purposeThis study utilizes FLT PET/CT imaging to characterize changes in tumor cell proliferation and vasculature during intermittent treatment with VEGR-TKI axitinib.

methodsPatients with metastatic solid malignancies underwent 3-week treatment cycles with axitinib (7 and 5 mg BID for safety and pharmacodynamic cohorts, respectively). Cycles consisted of 2 weeks of treatment (dosing period) followed by a 1-week treatment break (washout period). Patients in the pharmacodynamic cohort had up to six FLT PET/CT scans (three scans in each cycle 1 and cycle 3) and had plasma VEGF concentrations measured at imaging timepoints. Changes in tumor SUVs and VEGF within and across drug cycles were investigated.

resultsEight patients enrolled in the safety cohort where it was determined 7 mg axitinib was not tolerable due to severe adverse events, including three patients who experienced significant hypertension and thrombovascular effects. Sixteen patients enrolled in the pharmacodynamic cohort demonstrated significant decreases in SUVs and increases in VEGF during dosing periods. This was followed by significant increases in SUVs and decreases in VEGF during drug washout periods. No significant differences in SUVs or VEGF were found when comparing cycle 1 with cycle 3. A mixed effects model demonstrated significant negative correlation between SUV and VEGF.

conclusionsResponse to axitinib included diminished FLT uptake during dosing periods followed by increased FLT uptake during drug washout periods. These changes were not different when comparing treatment cycle 1 versus cycle 3, suggesting that the pharmacodynamic effect of intermittent axitinib is similar across multiple drug cycles.

Indexed as

AdultAgedAged, 80 and overAxitinibDideoxynucleosidesDrug Administration ScheduleFemaleHumansImidazolesIndazolesMaleMiddle AgedNeoplasmsPositron Emission Tomography Computed TomographyProtein Kinase InhibitorsVascular Endothelial Growth Factor AalovudineAxitinibDideoxynucleosidesImidazolesIndazolesProtein Kinase InhibitorsVascular Endothelial Growth Factor AAnti-angiogenic therapyAxitinibFLT PETPharmacodynamicTumor cell proliferationTyrosine kinase inhibitorVEGF

Identifiers

PMID27817059
PMCPMC5209788

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.